Precision Neuroscience Closes $250M Series D for Brain-Computer Interface Push

Precision Neuroscience has raised $250 million in a Series D round to advance its brain-computer interface technology, one of the largest single financing rounds to date in the implantable cortical recording sector.

The round brings renewed capital to a company working on devices designed to record neural activity directly from the cortical surface. For clinical neurophysiology readers, the company's platform is best understood as a next-generation iteration of the electrode technology already familiar from electrocorticography (ECoG): arrays placed on or in the cortical surface that capture high-resolution brain signals for decoding into control outputs for external devices.

The financing signals sustained investor confidence in implanted brain-computer interfaces despite the field's long regulatory and clinical timelines. Precision Neuroscience is competing in a space that includes Neuralink and several other ventures pursuing high-channel-count cortical interfaces intended ultimately for patients with paralysis and other neurological impairments.

The company has previously described its thin-film electrode array as designed to sit on the surface of the brain, an approach intended to avoid penetrating neural tissue while still capturing large numbers of channels of neural data. Surface-based ECoG-style recording carries practical implications for the monitoring unit: it leverages signal characteristics that epileptologists and neurophysiologists already interpret during invasive monitoring for seizure localization, including high-frequency oscillations and broadband power changes.

The Series D capital will support continued development of the interface technology toward human clinical applications. The company faces a regulatory pathway in which such devices remain investigational in the United States until FDA clearance or approval for specific indications — a distinction reading-room and lab audiences will recognize as central to evaluating claims in this space.

Investors are effectively betting that high-channel-count cortical recording can move beyond epilepsy monitoring and intraoperative mapping into restorative applications: translating decoded neural signals into device control for patients who have lost motor function.

The $250 million raise positions Precision Neuroscience to accelerate its clinical and engineering milestones in the coming years, as the race to bring implantable brain-computer interfaces from investigational prototypes into regulated patient care intensifies.